FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

AstraZeneca on expanding its diabetes research franchise

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

Amarin hit hard as generics loom for fish oil drug Vascepa

Novartis plots cardio trial in UK as London HQ opens

Novartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a new headquarters in London.

German court blocks Sanofi's cholesterol drug after Amgen la...

Amgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a patent blocking Sanofi from marketing its rival injected cholesterol drug in the co

Amarin’s Vascepa gets priority review for cardiovascular lab...

Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25